# A Study Of Stellate Ganglion Blockade With Liposomal Bupivacaine In Preventing Atrial Fibrillation After Isolated Coronary Artery Bypass Grafting Surgery

> **NCT07570940** · PHASE4 · NOT_YET_RECRUITING · sponsor: **Mayo Clinic** · enrollment: 450 (estimated)

## Conditions studied

- Coronary Artery Disease
- Atrial Fibrillation

## Interventions

- **DRUG:** Liposomal bupivacaine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07570940
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06
- **Primary completion:** 2030-06
- **Final completion:** 2030-06
- **Target enrollment:** 450 (ESTIMATED)
- **Last updated:** 2026-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07570940

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07570940, "A Study Of Stellate Ganglion Blockade With Liposomal Bupivacaine In Preventing Atrial Fibrillation After Isolated Coronary Artery Bypass Grafting Surgery". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07570940. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*